Comparative Pharmacology
Head-to-head clinical analysis: ANTARA MICRONIZED versus FIBRICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTARA MICRONIZED versus FIBRICOR.
ANTARA (MICRONIZED) vs FIBRICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor alpha (PPARα). This leads to increased lipolysis and elimination of triglyceride-rich particles from plasma by inducing lipoprotein lipase activity and reducing production of apolipoprotein C-III.
FIBRICOR (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, and reduces production of apolipoprotein C-III (an inhibitor of lipoprotein lipase). This leads to decreased triglyceride and increased HDL cholesterol levels.
Oral: 130 mg once daily with or without food. Capsules should be swallowed whole; do not crush or chew.
FIBRICOR (fenofibric acid) is dosed as 45 mg or 135 mg orally once daily, with or without food. The typical adult dose is 135 mg daily. For mixed dyslipidemia, the recommended dose is 135 mg once daily; for severe hypertriglyceridemia, start with 45 to 135 mg once daily, titrating based on response.
None Documented
None Documented
Terminal elimination half-life is approximately 15–17 hours (range 13–22 hours) in normolipidemic subjects; in hypertriglyceridemic patients, half-life may be prolonged up to 24–33 hours due to increased volume of distribution. Repeated dosing leads to steady state by about 4–5 days.
Terminal elimination half-life is approximately 20 hours (range 19-26 hours) in healthy volunteers, with clinical context indicating that steady state is achieved within 1 week of dosing.
Renal (approximately 70% of a dose is excreted in the urine, primarily as the glucuronide conjugate; less than 10% is excreted as unchanged drug in urine); fecal/biliary elimination accounts for about 20% (mainly as unchanged drug and metabolites via bile).
Approximately 60-70% of the dose is excreted renally as unchanged drug or glucuronide conjugate, and about 20-25% is excreted fecally. Biliary excretion is minimal.
Category C
Category C
Fibrate
Fibrate